Jazz Pharmaceuticals (JAZZ) Price Target Raised After Modeyso Commercial Strategy Update

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the best mid-cap stocks with huge upside potential. Truist Securities reaffirmed its Buy rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and boosted its price target from $200 to $205 on August 28. The update comes after Jazz’s webcast, which focused on the company’s marketing approach for Modeyso (dordaviprone), a recently licensed medication that treats an extremely rare type of aggressive glioma with an H3 K27M mutation.

According to Truist Securities, Modeyso is well-positioned for “robust commercial uptake” in the market due to the lack of competition for this high-unmet-need brain tumor. Additionally, the firm noted that Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was granted a Priority Review Voucher (PRV) for the clearance, whose estimated market worth exceeds $150 million.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biopharmaceutical company that develops treatments for serious illnesses. Its key products include Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos.

While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.